Amino acids and their transporters in T cell immunity and cancer therapy

W Wang, W Zou - Molecular cell, 2020 - cell.com
Metabolism reprogramming is critical for both cancer progression and effective immune
responses in the tumor microenvironment. Amino acid metabolism in different cells and their …

Signaling pathways in cancer metabolism: mechanisms and therapeutic targets

M You, Z Xie, N Zhang, Y Zhang, D Xiao, S Liu… - … and Targeted Therapy, 2023 - nature.com
A wide spectrum of metabolites (mainly, the three major nutrients and their derivatives) can
be sensed by specific sensors, then trigger a series of signal transduction pathways and …

The diagnosis and management of NK/T-cell lymphomas

E Tse, YL Kwong - Journal of hematology & oncology, 2017 - Springer
Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignancy of putative NK-
cell origin, with a minority deriving from the T-cell lineage. Pathologically, the malignancy …

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim… - The lancet …, 2016 - thelancet.com
Background The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has
improved substantially as a result of new treatment strategies with non-anthracycline-based …

NK-/T-cell lymphomas

H Wang, B Fu, RP Gale, Y Liang - Leukemia, 2021 - nature.com
Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein–Barr virus (EBV)-related non-
Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its …

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

X Bi, H Wang, W Zhang, J Wang, W Liu, Z Xia… - Journal of hematology & …, 2016 - Springer
Background Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus (EBV)-
associated, highly aggressive lymphoma. Treatment outcome remains sub-optimal …

Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type

M Yamaguchi, R Suzuki… - Blood, The Journal of the …, 2018 - ashpublications.org
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) is a subtype of mature T-and
natural killer cell lymphomas characterized by its association with Epstein-Barr virus and …

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell …

M Yamaguchi, YL Kwong, WS Kim, Y Maeda… - Journal of clinical …, 2011 - ascopubs.org
Purpose To explore a more effective treatment for newly diagnosed stage IV, relapsed, or
refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a …

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

SJ Kim, JQ Lim, Y Laurensia, J Cho… - Blood, The Journal …, 2020 - ashpublications.org
This study aimed to assess the efficacy and safety of treatment with avelumab, an anti–
programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory …

Anticancer activity of bacterial proteins and peptides

TM Karpiński, A Adamczak - Pharmaceutics, 2018 - mdpi.com
Despite much progress in the diagnosis and treatment of cancer, tumour diseases constitute
one of the main reasons of deaths worldwide. The side effects of chemotherapy and drug …